ClinicalTrials.gg
Not yet recruitingNCT07876284Updated Oct 21, 2026

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis

A Phase 1 interventional study of CHF10073 low dose and CHF10073 high dose in Idiopathic Pulmonary Fibrosis, sponsored by Chiesi Farmaceutici S.p.A.. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

Updated Oct 21, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The objective of the study is to assess the safety and tolerability of repeated doses of CHF10073 and to characterise cough-related safety outcomes associated with CHF10073 administration. In addition, the study will also characterise the PK (pharmacokinetics) profile in plasma after repeated administrations of study drug.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

This study's planned enrollment of 18 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained before any study-related procedure.
  • Male or female participant of any race, aged 40 years or older.
  • Diagnosis of idiopathic pulmonary fibrosis according to the 2018 and 2022 ATS/ERS/JRS/ALAT Guidelines for no more than 8 years before Screening, confirmed by centrally reviewed high-resolution computed tomography obtained within 12 months before Screening or performed during Screening.
  • Receiving locally approved idiopathic pulmonary fibrosis monotherapy at a stable dose for at least 8 weeks before Screening, or not receiving such monotherapy, including discontinuation at least 4 weeks before Screening.
  • Forced vital capacity at least 45% predicted and pre-bronchodilator /forced vital capacity ratio at least 0.7.
  • Diffusing capacity of the lung for carbon monoxide, corrected for , at least 25% predicted.
  • Peripheral oxygen saturation greater than 90% after 5 minutes at rest on room air or with protocol-specified supplemental oxygen.
  • Ability to correctly use the device after training with placebo.
  • Nonsmoker or ex-smoker meeting protocol-defined cessation periods and willing to abstain from all inhaled smoking products throughout the study.
  • Female participant meeting protocol definitions for non- or, if of childbearing potential, meeting pregnancy-testing and requirements.
  • Male participant meeting protocol-defined fertility and contraception requirements

Exclusion criteria

Exclusion Criteria:

  • Lower respiratory tract infection requiring antibiotics within 4 weeks before Screening or documented acute exacerbation of idiopathic pulmonary fibrosis within 3 months before Screening.
  • Planned major surgery during the study or history of lung resection.
  • Active or prior lung cancer.
  • Active cancer or cancer history with less than 5 years disease-free survival, except adequately treated localized carcinoma.
  • Emphysema involving at least 50% of the lung on high-resolution computed tomography or emphysema greater in extent than fibrosis.
  • End-stage fibrotic disease expected to require organ transplantation within 6 months.
  • uncontrolled medical or psychiatric disorders that may interfere with study completion or increase risk.
  • Other non-idiopathic pulmonary fibrosis pulmonary condition that may affect forced vital capacity.
  • reater than or equal to 35.0 kg/m² or recent excessive unexplained weight loss.
  • Clinically significant abnormal 12-lead ; interval using Fridericia's formula greater than 450 milliseconds for males or greater than 470 milliseconds for females.
  • Clinically significant cardiovascular condition that would preclude participation.
  • Significant neurologic disease, including protocol-specified recent , stroke, seizure, uncontrolled seizure disorder, or clinically significant behavioral or psychiatric disturbance.
  • Recent or current systemic , , cytotoxic therapy, pulmonary hypertension vasodilator therapy, inhaled bronchodilator, or inhaled corticosteroid use within protocol-specified periods.
  • Concomitant treatment with more than one locally approved idiopathic pulmonary fibrosis therapy.
  • Participation in another drug trial within 3 months or 5 half-lives of that drug, whichever is longer.
  • New or unresolved infection within 7 days before Screening or randomization, except respiratory infections addressed separately.
  • Known intolerance or to formulation or another substance used in the trial.
  • Use of non permitted concomitant medication as per protocol.
  • Clinically relevant abnormal laboratory values requiring investigation or potentially affecting safety or study evaluation.
  • Positive type 1 or type 2 test at Screening.
  • Positive hepatitis test indicating acute or chronic or C at Screening.
  • Documented alcohol or drug abuse within 12 months before Screening.
  • Pregnant or lactating female participant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    CHF10073 low dose

    Drug: CHF10073 low dose

  • Experimental
    CHF10073 high dose

    Drug: CHF10073 high dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugCHF10073 low dose

    Multiple doses of CHF10073

  • DrugCHF10073 high dose

    Multiple doses of CHF10073

  • DrugPlacebo

    Multiple doses of placebo

06

What researchers measure

Primary outcomes

  1. Number and % of participants with treatment-emergent adverse events, adverse drug reactions, serious and non-serious events, related and non-related events, severe events, events leading to discontinuation and events leading to death

    Time frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose

  2. Change from baseline in systolic and diastolic blood pressure

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose

  3. Change from baseline in pulse rate

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose

  4. Change from baseline in respiratory rate

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose

  5. Change from baseline in body temperature

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose

  6. Change from baseline in oxygen saturation

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose

  7. Number and percentage of participants with a change from baseline greater than 20 mmHg in systolic blood pressure and greater than 10 mmHg in diastolic blood pressure.

    Time frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose

  8. Change from baseline in ECG heart rate

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)

  9. Change from baseline in ECG intervals: PR interval and QT interval corrected using Fridericia's formula.

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)

  10. Change from baseline in ECG: QRS duration

    Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)

  11. Number and percentage of participants with an increase from baseline in QT interval corrected using Fridericia's formula greater than 30 milliseconds and greater than 60 milliseconds.

    Time frame: Day 1 through Day 28 (up to Follow-up visit, 35 to 42 days after the last dose for UK)

  12. Number and percentage of male participants with post-dose QT interval corrected using Fridericia's formula greater than 450, 480, and 500 milliseconds and female participants with values greater than 470 and 500 milliseconds

    Time frame: Day 1 through Day 28 (up to Follow-up visit, 35 to 42 days after the last dose for UK)

  13. Change and shift from baseline in clinical chemistry, including fasting glucose, and hematology evaluations

    Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics.

    Time frame: Day 1, Day 14 and Day 28 at pre-dose

  14. Change from baseline in forced vital capacity and forced expiratory volume in 1 second.

    Time frame: Day 1 , Day 14 and Day 28 at pre-dose and 30 minutes post-dose

Secondary outcomes

  1. Number and percentage of participants experiencing cough treatment-emergent adverse events

    Time frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose

  2. Plasma pharmacokinetic parameter AUC0-t for CHF10073.

    Time frame: Day 1 and Day 28

  3. Maximum observed plasma concentration (Cmax) of CHF10073.

    Time frame: Day 1 and Day 28

  4. Time to reach maximum observed plasma concentration (tmax) of CHF10073

    Time frame: Day 1 and Day 28

  5. Dose proportionality assessment using dose-normalized, log-transformed AUC0-t and Cmax as applicable.

    Time frame: Day 1 and Day 28

  6. Plasma concentration-time profiles summarized by dose level and study day

    Time frame: Day 1, Day 14, Day 28, and Follow-up, 35 to 42 days after the last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 9 months is close to that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Nov 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
2 edited, 2 added, 1 description edited
What changed in the outcomes
  • EditedChange from baseline in pulse rate, respiratory rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  • EditedChange from baseline in ECG intervals: PR interval, QRS duration, and QT interval corrected using Fridericia's formula.Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  • AddedChange from baseline in respiratory rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  • AddedChange from baseline in ECG: QRS durationTime frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  • DescriptionChange and shift from baseline in clinical chemistry, including fasting glucose, and hematology evaluations: how it is measured was reworded
Oct 21, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of cough events and number and percentage of participants experiencing cough treatment-emergent adverse eventsTime frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose
Oct 21, 2026
Registered
First appeared on the registry
Oct 15, 2026
Show all 2 updates
  1. Oct 21, 2026
    Primary outcomes 2 edited, 2 added, 1 description edited
    What changed in the outcomes
    • EditedChange from baseline in pulse rate, respiratory rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
    • EditedChange from baseline in ECG intervals: PR interval, QRS duration, and QT interval corrected using Fridericia's formula.Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
    • AddedChange from baseline in respiratory rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
    • AddedChange from baseline in ECG: QRS durationTime frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
    • DescriptionChange and shift from baseline in clinical chemistry, including fasting glucose, and hematology evaluations: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of cough events and number and percentage of participants experiencing cough treatment-emergent adverse eventsTime frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876284
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Chiesi Clinical Trial info
Contact
clinicaltrials_info@chiesi.com
+39 0521 2791
Pilar Rivera Ortega, MD
principal investigator · Royal Devon and Exeter Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion